Latin America Immunosuppressant Drugs Market 2019-2028

MARKET OUTLOOK

The immunosuppressant drugs market in Latin America has been projected to depict growth in terms of revenue and expand with a CAGR of 5.94% during the forecast years 2019-2028, according to a report by the publisher.
Brazil, Mexico, and countries in Rest of Latin America together shape the immunosuppressant drugs market in the Latin American region.

The Argentine pharmaceutical market is estimated to garner $15 billion by 2020. It is one of the highest valued markets in Latin America. People in the country have access to different healthcare services by means of Social Security schemes and health insurance plans and the availability of public hospitals. The percentage of healthcare expenditure is also very high. The growth of the pharmaceutical industry implies an increase in the demand for immunosuppressant drugs. The growth in demand has pushed forward the market growth for these drugs, in turn.

Further, around 6000 dialysis patients in the nation are waiting for kidney replacement. Around 55 government-approved kidney transplantation centers are present in the country. There are also numerous transplant centers for patients suffering from various conditions related to heart, liver, lung, and intestines. The growth in the number of organ transplantations taking place is favoring the growing demand for immunosuppressant drugs in Argentina. This is benefiting its immunosuppressant drugs market.

COMPETITIVE OUTLOOK

The major competitors in this market include Intas Pharmaceuticals Ltd (Accord Healthcare), Sanofi, Allergan (acquired by Abbvie Inc), Cipla Ltd, Veloxis Pharmaceuticals Inc, Abbvie Inc, Janssen Pharmaceuticals Inc (Johnson & Johnson Services Inc), Bristol-Myers Squibb Company, and GlaxoSmithKline plc.

1. Latin America Immunosuppressant Drugs Market - Summary

2. Industry Outlook

2.1. Market Definition
2.2. Key Insights
2.2.1. Organ Transplantation Leads Market by End-User
2.2.2. Pharmaceutical Industry Showing Growth Trends
2.2.3. Impact of Covid-19 on Transplant Recipients
2.3. Evolution & Transition of Immunosuppressant Drugs
2.4. Porter's Five Force Analysis
2.4.1. Threat of New Entrants
2.4.2. Threat of Substitute
2.4.3. Bargaining Power of Suppliers
2.4.4. Bargaining Power of Buyers
2.4.5. Threat of Competitive Rivalry
2.5. Market Attractiveness Index
2.6. Vendor Scorecard
2.7. Market Drivers
2.7.1. Demand from Organ Transplantation
2.7.2. Rise in the Number of Autoimmune Disorders
2.8. Market Restraints
2.8.1. Side-Effects of Immunosuppressant Drugs
2.9. Market Opportunities
2.9.1. Demand from Emerging Economies
2.9.2. Exports of Drugs and Medicine Worldwide on Rise
2.10. Market Challenges
2.10.1. Lack of Awareness About Organ Donation

3. Latin America Immunosuppressant Drugs Market Outlook – by Drug Class

3.1. Corticosteroids
3.2. Monoclonal Antibodies
3.3. Calcineurin Inhibitors
3.4. Mtor Inhibitors
3.5. Others

4. Latin America Immunosuppressant Drugs Market Outlook - by Distribution Channel

4.1. Hospital Pharmacies
4.2. Retail Pharmacies
4.3. Online Pharmacies

5. Latin America Immunosuppressant Drugs Market Outlook - by End-User

5.1. Organ Transplantation
5.2. Autoimmune Disorders
5.3. Others

6. Latin America Immunosuppressant Drugs Market – Regional Outlook

6.1. Brazil
6.2. Mexico
6.3. Rest of Latin America

7. Competitive Landscape

7.1. Abbvie Inc
7.2. Allergan (Acquired by Abbvie Inc)
7.3. Astellas Pharma Inc
7.4. Bristol-Myers Squibb Company
7.5. Cipla Ltd
7.6. Dr Reddys Laboratories Ltd
7.7. F Hoffmann-La Roche Ltd
7.8. GlaxoSmithKline plc
7.9. Intas Pharmaceuticals Ltd (Accord Healthcare)
7.10. Janssen Pharmaceuticals Inc (Johnson & Johnson Services Inc)
7.11. Mylan Nv
7.12. Novartis AG
7.13. Pfizer Inc
7.14. Sanofi
7.15. Veloxis Pharmaceuticals Inc

8. Methodology & Scope

8.1. Research Scope
8.2. Sources of Data
8.3. Research Methodology

List of Tables

Table 1: Latin America Immunosuppressant Drugs Market, by Country, 2019-2028 (In $ Million)
Table 2: Market Attractiveness Index
Table 3: Vendor Scorecard
Table 4: Side-Effects of Immunosuppressant Drugs
Table 5: Top 15 Positive Net Exports Countries and Negative Net Exports for Drugs & Medicines Countries
Table 6: Latin America Immunosuppressant Drugs Market, by Drug Class, 2019-2028 (In $ Million)
Table 7: Latin America Immunosuppressant Drugs Market, by Distribution Channel, 2019-2028 (In $ Million)
Table 8: Latin America Immunosuppressant Drugs Market, by End-User, 2019-2028 (In $ Million)
Table 9: Latin America Immunosuppressant Drugs Market, by Country, 2019-2028 (In $ Million)

List of Figures

Figure 1: Evolution & Transition of Immunosuppressant Drugs
Figure 2: Porter's Five Force Analysis
Figure 3: Latin America Immunosuppressant Drugs Market, by Corticosteroids, 2019-2028 (In $ Million)
Figure 4: Latin America Immunosuppressant Drugs Market, by Monoclonal Antibodies, 2019-2028 (In $ Million)
Figure 5: Latin America Immunosuppressant Drugs Market, by Calcineurin Inhibitors, 2019-2028 (In $ Million)
Figure 6: Latin America Immunosuppressant Drugs Market, by Mtor Inhibitors, 2019-2028 (In $ Million)
Figure 7: Latin America Immunosuppressant Drugs Market, by Others, 2019-2028 (In $ Million)
Figure 8: Latin America Immunosuppressant Drugs Market, by Hospital Pharmacies, 2019-2028 (In $ Million)
Figure 9: Latin America Immunosuppressant Drugs Market, by Retail Pharmacies, 2019-2028 (In $ Million)
Figure 10: Latin America Immunosuppressant Drugs Market, by Online Pharmacies, 2019-2028 (In $ Million)
Figure 11: Latin America Immunosuppressant Drugs Market, by Organ Transplantation, 2019-2028 (In $ Million)
Figure 12: Latin America Immunosuppressant Drugs Market, by Autoimmune Disorders, 2019-2028 (In $ Million)
Figure 13: Latin America Immunosuppressant Drugs Market, by Others, 2019-2028 (In $ Million)
Figure 14: Latin America Immunosuppressant Drugs Market, Regional Outlook, 2019 & 2028 (In %)
Figure 15: Brazil Immunosuppressant Drugs Market, 2019-2028 (In $ Million)
Figure 16: Mexico Immunosuppressant Drugs Market, 2019-2028 (In $ Million)
Figure 17: Rest of Latin America Immunosuppressant Drugs Market, 2019-2028 (In $ Million)